Leader in therapeutic antibodies adopts Genedata Biologics for its central research and development IT infrastructure
Bssel, Switzerland (PRWEB) September 27, 2011
“Therapeutic antibodies are one of the fastest-growing drug classes in human healthcare,” said Dr. Markus Enzelberger, vice president and head of Discovery Alliances and Technologies at MorphoSys. “To advance our leadership in this field, our biopharma R&D operations require an integrated and scalable informatics infrastructure that can be tailored to support our biologics discovery processes. Genedata Biologics provides comprehensive biologics data management functionality and the flexibility needed to support our proprietary antibody discovery processes and technology portfolio. And, it provides this functionality out-of-the-box, which saves valuable research time and money.”
First-in-Class Biologics Data Management
Genedata Biologics is the industry’s first-in-class biologics data management system. Out-of-the-box, it processes and manages data from diverse library, selection, screening, and expression technologies and strategies. It provides end-to-end laboratory workflow support, spanning: library registration; selection and planning; screening; hit selection; expression; purification; and analytics.
The system’s integrated decision support tools enable the identification of the most promising molecules for development. These tools also provide transparent guidance for downstream expression, purification, characterization, and assessment of candidate molecules.
Inherently flexible, Genedata Biologics is easily configured to address corporate-specific and proprietary workflows and technology requirements. This is accomplished by an integrated yet open molecule and sample management platform, and interfaces for assay and analytics instrument integration. A comprehensive set of APIs enables integration with existing corporate IT infrastructures.
“MorphoSys is pioneering antibody discovery and we are delighted they have selected Genedata Biologics as their central discovery IT infrastructure,” said Dr. Othmar Pfannes, CEO of Genedata. “MorphoSys’ adoption of Genedata Biologics is another major milestone for our growing biopharma business. We will continue to invest in the advancement of protein therapeutics, and support those engaged in the field including pharmaceutical and biotechnology companies, technology providers, CROs, CMOs, and emerging biosimilar companies.”
About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company’s AbD Serotec unit uses HuCAL and other technologies to generate superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead, and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, Genedata Selector™, and Genedata Biologics™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany, and the US. http://www.genedata.com.
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
###
Allison Kurz
Genedata
+41 61 511 8459
Email Information
There are no comments yet